Gene Biotherapeutics (Gene Biotherapeutics) Dividends per Share : $0.00 (TTM As of Dec. 2020)

View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Dividends per Share?

Gene Biotherapeutics's dividends per share for the three months ended in Dec. 2020 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2020 was $0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2020 was 0.00. As of today, Gene Biotherapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Gene Biotherapeutics Dividends per Share Historical Data

The historical data trend for Gene Biotherapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Dividends per Share Chart

Gene Biotherapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dividends per Share

Get a 7-Day Free Trial

Gene Biotherapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Gene Biotherapeutics's Dividends per Share

For the Biotechnology subindustry, Gene Biotherapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gene Biotherapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's Dividend Yield % falls into.

Gene Biotherapeutics Dividends per Share Calculation

Dividends paid to per common share.

Gene Biotherapeutics (OTCPK:CRXM) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Gene Biotherapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2020 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2020 )	/	EPS without NRI (Q: Dec. 2020 )
	=	0	/	-0.017
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Gene Biotherapeutics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121

Website

https://www.genebiotherapeutics.com

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Executives

Andrew M Leitch	director	6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison	director	C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy	officer: Chief Financial Officer
Ronald I Simon	other: Former Director	485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten	director, officer: PRESIDENT and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines

From GuruFocus

Baron Funds Comments on CarMax Inc.

By Holly LaFon • 02-06-2013

Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation

By PRNewswire PRNewswire • 09-05-2018

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010